Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1554

1.

Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.

Lee JW, Iwahashi A, Hasegawa S, Yonezawa T, Jeon WB, Cha BY, Nagai K, Woo JT.

J Nat Med. 2012 Jan;66(1):8-16. doi: 10.1007/s11418-011-0537-7. Epub 2011 Jun 9.

PMID:
21656335
2.

Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.

Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP.

J Bone Miner Res. 2005 Sep;20(9):1659-68. Epub 2005 May 2.

3.

Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.

Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH.

Mol Pharmacol. 2010 Jan;77(1):17-25. doi: 10.1124/mol.109.057877. Epub 2009 Oct 14.

4.

Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.

Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.

Biochem Pharmacol. 2013 Sep 15;86(6):782-90. doi: 10.1016/j.bcp.2013.07.015. Epub 2013 Aug 6.

PMID:
23928189
5.

Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.

Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, Umezawa K.

J Bone Miner Res. 2005 Apr;20(4):653-62. Epub 2004 Dec 6.

7.

Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.

Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.

J Bone Miner Res. 2011 Mar;26(3):644-56. doi: 10.1002/jbmr.242.

8.

Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways.

Hu JP, Nishishita K, Sakai E, Yoshida H, Kato Y, Tsukuba T, Okamoto K.

Eur J Pharmacol. 2008 Feb 2;580(1-2):70-9. Epub 2007 Nov 17.

PMID:
18083161
9.

Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.

Kim HN, Ha H, Lee JH, Jung K, Yang D, Woo KM, Lee ZH.

Eur J Pharmacol. 2009 Nov 25;623(1-3):22-9. doi: 10.1016/j.ejphar.2009.09.025. Epub 2009 Sep 17.

PMID:
19766111
10.

Bone morphogenetic protein 2 enhances mouse osteoclast differentiation via increased levels of receptor activator of NF-κB ligand expression in osteoblasts.

Tachi K, Takami M, Zhao B, Mochizuki A, Yamada A, Miyamoto Y, Inoue T, Baba K, Kamijo R.

Cell Tissue Res. 2010 Nov;342(2):213-20. doi: 10.1007/s00441-010-1052-y. Epub 2010 Oct 13.

PMID:
20941510
11.

Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.

Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K, Nakagawa N, Yasuda H, Goto M, Tsuda E, Higashio K, Gillespie MT, Martin TJ, Suda T.

Bone. 1999 Nov;25(5):517-23.

PMID:
10574571
12.
13.

Alisol-B, a novel phyto-steroid, suppresses the RANKL-induced osteoclast formation and prevents bone loss in mice.

Lee JW, Kobayashi Y, Nakamichi Y, Udagawa N, Takahashi N, Im NK, Seo HJ, Jeon WB, Yonezawa T, Cha BY, Woo JT.

Biochem Pharmacol. 2010 Aug 1;80(3):352-61. doi: 10.1016/j.bcp.2010.04.014. Epub 2010 Apr 20.

PMID:
20412788
15.

Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo.

Yonezawa T, Hasegawa S, Asai M, Ninomiya T, Sasaki T, Cha BY, Teruya T, Ozawa H, Yagasaki K, Nagai K, Woo JT.

Eur J Pharmacol. 2011 Jan 15;650(2-3):511-8. doi: 10.1016/j.ejphar.2010.10.048. Epub 2010 Nov 1.

PMID:
21047508
16.

Mineral trioxide aggregate solution inhibits osteoclast differentiation through the maintenance of osteoprotegerin expression in osteoblasts.

Hashiguchi D, Fukushima H, Nakamura M, Morikawa K, Yasuda H, Udagawa N, Maki K, Jimi E.

J Biomed Mater Res A. 2011 Feb;96(2):358-64. doi: 10.1002/jbm.a.32990. Epub 2010 Dec 6.

PMID:
21171155
17.

Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation.

Suda K, Udagawa N, Sato N, Takami M, Itoh K, Woo JT, Takahashi N, Nagai K.

J Immunol. 2004 Feb 15;172(4):2504-10.

18.

Osteoblastic NF-κB pathway is involved in 1α, 25(OH)2D3-induced osteoclast-like cells formation in vitro.

Cong L, Zhang C, Tu G.

Int J Clin Exp Pathol. 2015 May 1;8(5):5988-96. eCollection 2015.

20.

The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.

Peng S, Liu XS, Huang S, Li Z, Pan H, Zhen W, Luk KD, Guo XE, Lu WW.

Bone. 2011 Dec;49(6):1290-8. doi: 10.1016/j.bone.2011.08.031. Epub 2011 Sep 9.

PMID:
21925296
Items per page

Supplemental Content

Write to the Help Desk